Corrigendum to “Effects of Shenfu Injection in the Treatment of Septic Shock Patients: A Multicenter, Controlled, Randomized, Open‐Label Trial”
Yi Li(Sichuan University), Xuezhong Yu(Beijing Union University), Yu Cao(China Pharmaceutical University), Chuanyun Qian(Kunming Medical University), Haibo Qiu(Zhongda Hospital Southeast University), Zhigang Shan(PLA 306 Hospital), Joseph Harold Walline(Chinese University of Hong Kong), Peihong Lin(Fujian Medical University), Xinchao Zhang(Shandong University), Jie Wei(Wuhan University), Shuming Pan(XinHua Hospital)
Cited by 3
Related Papers
Potentially modifiable factors contributing to outcome from acute respiratory distress syndrome: the LUNG SAFE study
|Intensive Care Medicine|2016|387
Epidemiology and outcomes of hospital-acquired bloodstream infections in intensive care unit patients: the EUROBACT-2 international cohort study
|Intensive Care Medicine|2023|257
Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Patients with Sepsis: A Prospective Observational Study
|Mediators of Inflammation|2016|228
XueBiJing Injection Versus Placebo for Critically Ill Patients With Severe Community-Acquired Pneumonia: A Randomized Controlled Trial
|Critical Care Medicine|2019|164
USF2 knockdown downregulates THBS1 to inhibit the TGF-β signaling pathway and reduce pyroptosis in sepsis-induced acute kidney injury
|Pharmacological Research|2021|139